xtended periods of breast-feeding are common in many countries with high HIV-1 incidence (1), and normal physiologic changes in breast-feeding women may impact drug safety and pharmacokinetics (2) . Thus, biomedical HIV prevention strategies for women such as preexposure prophylaxis (PrEP) and topical microbicides should include those suitable during breastfeeding, especially considering higher infant transmission risk associated with incident maternal HIV-1 infection (3). However, both oral and topical HIV-1 chemoprophylaxis studies typically exclude breast-feeding women (1) . The U.S. Food and Drug Administration (FDA) has released draft guidance recommending lactation studies for drugs expected for use by reproductive-age women (4) . Here, we describe the first pharmacokinetic (PK) and safety study of topical antiretroviral (ARV) administration among breast-feeding mother-infant pairs.
In CAPRISA 004, participants randomly assigned to topical tenofovir (TFV) treatment had 39% reduction in HIV-1 (5) and halved risk of herpes simplex virus 2 (HSV-2) acquisition (6) compared to participants treated with placebo. Subsequent trials found no similar protection, presumably due to low adherence (7). Recent results from ASPIRE (8) showed protective benefit against HIV-1 infection for women using a dapivirine (DPV) intravaginal ring. Other studies are investigating tenofovir-containing intravaginal rings and drug transfer to breast milk following use of a DPV intravaginal ring (NCT02431273 and NCT02658227) (9) .
Previous work supports safety of single-dose topical TFV in HIV-1-uninfected pregnant women (10) and oral tenofovir disoproxil fumarate (TDF) treatment for HIV-1-infected pregnant women (11) . Oral TDF has not been associated with high serum or milk levels during breast-feeding (12, 13) . Low oral bioavailability for TFV has been assumed to preclude or reduce absorption by breast-feeding infants, although previously no data were available (14) . While TDF is not Food and Drug Administration approved or recommended for use in neonates or infants under 2 years, it is approved for children aged 2 to 12 years old when given as part of an antiretroviral therapy (ART) regimen. Treatment regimens containing TDF have been associated with gastrointestinal side effects (e.g., flatulence, diarrhea), as well as less common but more serious problems, such as bone and renal toxicity (15) .
MTN-008 (NCT01136759) was conducted in Pittsburgh, PA, and Birmingham, AL (2011 to 2013). The participants were HIV-1-negative women and their breast-feeding infants 4 to 26 weeks old. Women received first and last doses of 1% TFV gel intravaginally in the clinic on days 0 and 6 and self-inserted five daily doses between the first and last doses. The formulation of the TFV gel was identical to the product used for CAPRISA 004 and the VOICE study. On days 0 and 6, milk and blood samples were collected predose and 2, 4, and 6 h postdose; infant blood samples were collected 6 h after maternal dosing (1 to 4 h after breastfeeding). Study investigators made judgments about the potential relatedness of an adverse event (AE) to product exposure prior to pharmacokinetic analyses. Institutional review board approval was obtained, and participants provided written informed consent.
Blood was centrifuged after collection (Յ8 h), with serum frozen at Ϫ20°C. Milk was swirled to mix and transferred by pipette into cryogenic vials, with aliquots frozen immediately at Ϫ20°C or lower. Tenofovir concentrations were measured via liquid chromatography-tandem mass spectrometric analysis by validated methods (16, 17) . Lower limits of quantitation (LLOQ) were 0.31 ng/ml (serum) and 1.0 ng/ml (milk). Pharmacodynamic (PD) activity was assessed by the TZM-bl assay, (18) using serial dilutions of milk from baseline and 6 h after last dose. Analyses were conducted using SAS 9.2, IBM SPSS 22.0, and Stata 12.1. Wilcoxon rank sum tests were used to compare TFV levels by matrix on day 0 versus 6.
Seventeen pairs of women and infants enrolled in the study (Table 1) . Tenofovir was detected in serum samples from all women following the first dose (Table 2) . At day 6, serum tenofovir levels were detected for 56.3% of women predose and 100% of women postdose. A minority of milk samples had detectable TFV (25% at postdose day 0, 12.5% at predose day 6, and 37.5% at postdose day 6). The milk-to-maternal serum ratio for 18 samples where both were higher than the LLOQ was 0.91 (median) (interquartile range [IQR] of 0.43 to 1.34). Eight infants were male, and nine were female. Six infants (37.5%) had detectable TFV after maternal dosing on day 0 (two females and four males) and 75% of infants (n ϭ 12) postdose on day 6 (eight females and four males). Infant TFV concentrations were higher on day 6 than on day 0 (P Ͻ 0.03).
Pharmacodynamic activity in milk demonstrated measurable innate anti-HIV activity (baseline specimen) (Fig. 1 ). Day 6 milk had no additional anti-HIV activity attributable to TFV beyond baseline (not statistically significant).
Nine of 17 mothers experienced one or more AEs (total of 20 AEs), of which 9 (47%) were reproductive tract (all mild, 40% deemed related to gel, including genital burning, metrorrhagia, and diarrhea). Four of 17 infants had one or more AEs (total 8 Anti-HIV activity was measured before TFV treatment (baseline) and after TFV treatment (day 6/6 h) in specimens using the TZM-bl assay. Milk was modestly diluted (1:50) in assay medium. No difference in anti-HIV activity was noted between baseline and day 6 specimens (P ϭ 0.14 by Wilcoxon matched-pair signed-rank test), indicating that no anti-HIV activity could be attributed to TFV gel use.
AEs; 7/8 mild; one infant had diarrhea that was deemed related to TFV exposure). Eleven (73%) women reported inserting five doses at home, two (13%) reported inserting four doses, and two (13%) reported inserting six doses.
Vaginally administered TFV gel resulted in detectable TFV in milk and infant blood; however, only a small fraction of drug was transferred. While TFV is a small molecule, facilitating passage into milk, it has properties limiting transfer, including limited lipid solubility and protein binding (19) . Despite expectations, TFV was detectable in blood at low concentrations for 12/16 infants. While our sample was too small to assess the potential presence of gender differences in pharmacokinetic or safety profiles, we did not observe any trends suggesting this.
Breast milk TFV was quantifiable in only four women after dose 1 and in six women after dose 7, but there was no evidence of accumulation between doses. However, the number of infants with detectable serum TFV (n ϭ 6) exceeded the number of mothers with detectable TFV. Similarly, on day 6, TFV was detected in milk samples from only two mothers predosing and six mothers at postdosing, but 12 infants had detectable TFV in their sera. These findings may be related to differences in assay sensitivity-the LLOQ for the milk (1.0 ng/ml) and serum (0.31 ng/ml) samples differ-or maternal and infant drug clearance and, therefore, accumulation differences. We identified significant increases in infant serum TFV levels on day 6 (with slightly lower serum TFV concentrations in mothers), consistent with modest TFV accumulation in blood samples from breast-feeding infants, though not in their mothers. However, the absolute TFV levels detected were Ն100-fold below treatment effective concentrations and unlikely of clinical concern. These findings are supported by no observable pharmacodynamic activity in milk beyond innate activity using the TZM-bl assay. While there was a small 1-to 2-h difference in the median time to peak concentration (T max ) and the 6 h breast milk sample used for TZM-bl assay, a majority of these samples were coincident and, therefore, very closely representative of peak concentration and antiviral effect within the study population.
Previous studies of maternal oral TDF use have not reported significant safety concerns for breast-feeding infants. In HPTN 057, TFV was detected in 3/4 milk samples collected within 2 days of delivery (6.3 to 17.8 ng/ml), and in 1/21 collected 4 to 6 days after delivery following peripartum oral TDF use by HIV-infected mothers (15.7 ng/ml) (13) . In ANRS 12109, HIV-infected mothers administered oral TDF in labor and 7 days postpartum had milk TFV concentrations of 5.83 to 8.75 ng/ml (12) . Using milk TFV concentrations averaging higher than those here, Benaboud and colleagues simulated plasma TFV concentrations as 0.03% of proposed prophylactic doses for neonates (12) .
This study had several strengths, including directly observed doses and measurement of multiple matrices over time. Our findings showing few AEs are consistent with other tenofovir studies of mothers and infants. However, our ability to characterize safety is limited if adherence were overreported. We did not observe any correlation between adherence to the self-administration protocol and TFV levels detected in the mothers or infants. However, our sample size was small, and self-reported adherence was high overall. Variability in volume, frequency, and/or timing of infant feeding may have impacted our PK results; the frequency and duration of infant feeding were captured for study days 0 and 6, while participants were on-site for study visits (not on interim study days). Estimating the volume of ingested breast milk by maternal report is imprecise, and techniques to approximate intake using infant weight before and after feeding were not used in MTN-008. The interval between topical TFV administration and the next breastfeeding session was controlled for time in the clinic on days 0 and 6, but not for self-administered doses on days 2 through 5. Thus, it is possible that time-dependent variations in TFV in breast milk may be related to differences in TFV ingestion.
Medication use during breast-feeding should follow a careful risk/benefit assessment by the woman and her health care provider. Findings suggest low levels of drug transfer to milk and nursing infants associated with topically delivered TFV in mothers. Further study among breast-feeding mother-infant pairs should occur for topically formulated ARVs delivered via sustained release platforms, such as vaginal rings.
